Anticancer activity of 4-[1-oxo-(substituted aryl)-2-propenyl]-3- phenylsydnones

K. Satyanarayana, S.R. Deshpande, B.S. Rao, M.N.A. Rao

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Novel structural feature containing 4-[1-oxo-(substituted aryl)-2-propenyl]-3-phenylsydnones were synthesized and screened for anticancer activity. These compounds contain two pharmacophores,a,b unsaturated ketone moiety and sydnone nucleus. Three compounds were synthesized, and all of the three exhibited promising in vitro cytotoxicity in 56 cell lines representing cancers of non-small cell lung, colon, CNS, melanoma, ovarian, prostrate, breast and leukemia. Average growth inhibition of 50% was in the range of 1.7-3.5 μM. Methyl derivative was highly selective against SNB-75 tumor cell line of CNS. It was active at less than one nano mole. However, in vivo the activity was moderate by hollow fiber assay model.
Original languageEnglish
Pages (from-to)679-683
Number of pages5
JournalIndian Journal of Pharmaceutical Sciences
Volume66
Issue number5
Publication statusPublished - 2004

Fingerprint

Sydnones
Tumor Cell Line
Ketones
Non-Small Cell Lung Carcinoma
Melanoma
Colon
Leukemia
Breast
Cell Line
Growth
In Vitro Techniques
3-phenylsydnone

Cite this

Satyanarayana, K., Deshpande, S. R., Rao, B. S., & Rao, M. N. A. (2004). Anticancer activity of 4-[1-oxo-(substituted aryl)-2-propenyl]-3- phenylsydnones. Indian Journal of Pharmaceutical Sciences, 66(5), 679-683.
Satyanarayana, K. ; Deshpande, S.R. ; Rao, B.S. ; Rao, M.N.A. / Anticancer activity of 4-[1-oxo-(substituted aryl)-2-propenyl]-3- phenylsydnones. In: Indian Journal of Pharmaceutical Sciences. 2004 ; Vol. 66, No. 5. pp. 679-683.
@article{11e486add6034101a56335c09f9bbcf8,
title = "Anticancer activity of 4-[1-oxo-(substituted aryl)-2-propenyl]-3- phenylsydnones",
abstract = "Novel structural feature containing 4-[1-oxo-(substituted aryl)-2-propenyl]-3-phenylsydnones were synthesized and screened for anticancer activity. These compounds contain two pharmacophores,a,b unsaturated ketone moiety and sydnone nucleus. Three compounds were synthesized, and all of the three exhibited promising in vitro cytotoxicity in 56 cell lines representing cancers of non-small cell lung, colon, CNS, melanoma, ovarian, prostrate, breast and leukemia. Average growth inhibition of 50{\%} was in the range of 1.7-3.5 μM. Methyl derivative was highly selective against SNB-75 tumor cell line of CNS. It was active at less than one nano mole. However, in vivo the activity was moderate by hollow fiber assay model.",
author = "K. Satyanarayana and S.R. Deshpande and B.S. Rao and M.N.A. Rao",
note = "Cited By :10 Export Date: 10 November 2017 CODEN: IJSID Correspondence Address: Satyanarayana, K.; Natco Research Center, Natco Pharma Ltd., B-13, Sanathnagar, Hyderabad-500 018, India; email: dr_ksn@rediffmail.com References: Kier, L.B., (1967) J. Pharm.Sci, 56, p. 149; Newton, C.G., Ramsden, C.A., (1982) Tetrahedron, 38, p. 2965; Satyanarayana, K., Rao, M.N.A., (1995) J. Pharm. Sci, 84, p. 263; Satyanarayana, K., Rao, M.N.A., (1995) Eur. J. Med. Chem, 30, p. 641; Satyanarayana, K., Ra, M.N.A., (1995) Indian J. Pharm. Sci, pp. 57-243; Anto, R.J., Kuttan, R., Satyanarayana, K., Rao, M.N.A., (1994) J. Clin. Biochem. Nutr, 17, p. 73; Satyanarayana, K., Deshpande, R.S., Subba Rao, B., Rao, M.N.A., (2002) Indian Drugs, 39, p. 578; Ammon, H.P.T., Wah, M.A., (1991) Plant Med, 57, p. 1; Kuttan, R., Banumathi, P., Nirmala, K., George, M.C., (1985) Cancer Letters, 29, p. 197; Sreejayan and Rao, M.N.A., J. Pharm. Pharmacol., 1994, 46, 1013; Anto, R.J., Sukumaran, K., Kuttan, G., Rao, M.N.A., Subbaraju, U., Kuttan, R., (1995) Cancer Letters, 97, p. 3; Boyd, A.P., (1989) Amm. Assoc. Cancer Res, 30, p. 652; Monk, A.P., Scudiero, P., Skehan, P., Shoemaker, K.D., Poull, D., Vistica, C., Hose, J.L., Vaigro, W., (1991) J. Natl. Cancer Inst, pp. 83-757; Weinstein, J.N., Myers, T.G.O., Connors, S.H., Friend, A.J., Fornance, Jr, Kohn, K.W., J.K:, Buolamwini, W.W., Zaharevitz, D.W., Bunow, R.E., and Pauli, K.D., Science, 1997, 343; Vilpo, J.A., Vilpo, L.M., Vourinen, P., Moilanen, E., MestaKetela, T., (1997) Anticancer Drug Design, 12, p. 75; Drapier, J.D., Hibbs, J.B., (1988) J .Immunol, 140, p. 2829; Hibbs, J.B., Taintor, R.R., Vavrin, Z., (1987) Science, Wash DC, 235, p. 473",
year = "2004",
language = "English",
volume = "66",
pages = "679--683",
journal = "Indian Journal of Pharmaceutical Sciences",
issn = "0250-474X",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "5",

}

Satyanarayana, K, Deshpande, SR, Rao, BS & Rao, MNA 2004, 'Anticancer activity of 4-[1-oxo-(substituted aryl)-2-propenyl]-3- phenylsydnones', Indian Journal of Pharmaceutical Sciences, vol. 66, no. 5, pp. 679-683.

Anticancer activity of 4-[1-oxo-(substituted aryl)-2-propenyl]-3- phenylsydnones. / Satyanarayana, K.; Deshpande, S.R.; Rao, B.S.; Rao, M.N.A.

In: Indian Journal of Pharmaceutical Sciences, Vol. 66, No. 5, 2004, p. 679-683.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anticancer activity of 4-[1-oxo-(substituted aryl)-2-propenyl]-3- phenylsydnones

AU - Satyanarayana, K.

AU - Deshpande, S.R.

AU - Rao, B.S.

AU - Rao, M.N.A.

N1 - Cited By :10 Export Date: 10 November 2017 CODEN: IJSID Correspondence Address: Satyanarayana, K.; Natco Research Center, Natco Pharma Ltd., B-13, Sanathnagar, Hyderabad-500 018, India; email: dr_ksn@rediffmail.com References: Kier, L.B., (1967) J. Pharm.Sci, 56, p. 149; Newton, C.G., Ramsden, C.A., (1982) Tetrahedron, 38, p. 2965; Satyanarayana, K., Rao, M.N.A., (1995) J. Pharm. Sci, 84, p. 263; Satyanarayana, K., Rao, M.N.A., (1995) Eur. J. Med. Chem, 30, p. 641; Satyanarayana, K., Ra, M.N.A., (1995) Indian J. Pharm. Sci, pp. 57-243; Anto, R.J., Kuttan, R., Satyanarayana, K., Rao, M.N.A., (1994) J. Clin. Biochem. Nutr, 17, p. 73; Satyanarayana, K., Deshpande, R.S., Subba Rao, B., Rao, M.N.A., (2002) Indian Drugs, 39, p. 578; Ammon, H.P.T., Wah, M.A., (1991) Plant Med, 57, p. 1; Kuttan, R., Banumathi, P., Nirmala, K., George, M.C., (1985) Cancer Letters, 29, p. 197; Sreejayan and Rao, M.N.A., J. Pharm. Pharmacol., 1994, 46, 1013; Anto, R.J., Sukumaran, K., Kuttan, G., Rao, M.N.A., Subbaraju, U., Kuttan, R., (1995) Cancer Letters, 97, p. 3; Boyd, A.P., (1989) Amm. Assoc. Cancer Res, 30, p. 652; Monk, A.P., Scudiero, P., Skehan, P., Shoemaker, K.D., Poull, D., Vistica, C., Hose, J.L., Vaigro, W., (1991) J. Natl. Cancer Inst, pp. 83-757; Weinstein, J.N., Myers, T.G.O., Connors, S.H., Friend, A.J., Fornance, Jr, Kohn, K.W., J.K:, Buolamwini, W.W., Zaharevitz, D.W., Bunow, R.E., and Pauli, K.D., Science, 1997, 343; Vilpo, J.A., Vilpo, L.M., Vourinen, P., Moilanen, E., MestaKetela, T., (1997) Anticancer Drug Design, 12, p. 75; Drapier, J.D., Hibbs, J.B., (1988) J .Immunol, 140, p. 2829; Hibbs, J.B., Taintor, R.R., Vavrin, Z., (1987) Science, Wash DC, 235, p. 473

PY - 2004

Y1 - 2004

N2 - Novel structural feature containing 4-[1-oxo-(substituted aryl)-2-propenyl]-3-phenylsydnones were synthesized and screened for anticancer activity. These compounds contain two pharmacophores,a,b unsaturated ketone moiety and sydnone nucleus. Three compounds were synthesized, and all of the three exhibited promising in vitro cytotoxicity in 56 cell lines representing cancers of non-small cell lung, colon, CNS, melanoma, ovarian, prostrate, breast and leukemia. Average growth inhibition of 50% was in the range of 1.7-3.5 μM. Methyl derivative was highly selective against SNB-75 tumor cell line of CNS. It was active at less than one nano mole. However, in vivo the activity was moderate by hollow fiber assay model.

AB - Novel structural feature containing 4-[1-oxo-(substituted aryl)-2-propenyl]-3-phenylsydnones were synthesized and screened for anticancer activity. These compounds contain two pharmacophores,a,b unsaturated ketone moiety and sydnone nucleus. Three compounds were synthesized, and all of the three exhibited promising in vitro cytotoxicity in 56 cell lines representing cancers of non-small cell lung, colon, CNS, melanoma, ovarian, prostrate, breast and leukemia. Average growth inhibition of 50% was in the range of 1.7-3.5 μM. Methyl derivative was highly selective against SNB-75 tumor cell line of CNS. It was active at less than one nano mole. However, in vivo the activity was moderate by hollow fiber assay model.

M3 - Article

VL - 66

SP - 679

EP - 683

JO - Indian Journal of Pharmaceutical Sciences

JF - Indian Journal of Pharmaceutical Sciences

SN - 0250-474X

IS - 5

ER -